Athira Pharma Reports Second Quarter 2023 Financial Results and Pipeline and Business Updates
August 10, 2023 16:05 ET
|
Athira Pharma, Inc.
Completed end of Phase 2 meeting and continued engagement with U.S. Food and Drug AdministrationAppointed Andrew Gengos as Chief Financial Officer and Chief Business OfficerMaintains strong balance...
How High Is the Bar for Future ALS Treatments? Although Neurologists Express Frustration with Current Treatments, They Are Quick to Adopt Therapies that Promise to Delay ALS Progression
August 02, 2023 11:15 ET
|
Spherix Global Insights
Exton, Pennsylvania, Aug. 02, 2023 (GLOBE NEWSWIRE) -- A quiet but significant advance was made during the last year: not one, but two medicines were FDA approved to delay disease progression in the...
Pasithea Therapeutics publishes study in Proceedings of the National Academy of Sciences (PNAS) that shows an increase in α5 integrin expression in ALS human and mouse brain tissue, and further demonstrates targeting α5 integrin results in improved survival and motor function
August 01, 2023 07:59 ET
|
Pasithea
-- PAS-003 is a monoclonal antibody targeting α5/β1 integrin for the treatment of amyotrophic lateral sclerosis (“ALS”) -- -- Lead α5/β1 integrin drug candidate to be selected in H2 2023 -- ...
Amyotrophic Lateral Sclerosis Market to Surge Immensely by 2032, Predicts DelveInsight | Key Companies to Watch Out - Cytokinetics, Orphazyme, Orion, Biogen, AB Science, Ionis, Biohaven, MediciNova, NeuroSense
July 19, 2023 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, July 19, 2023 (GLOBE NEWSWIRE) -- Amyotrophic Lateral Sclerosis Market to Surge Immensely by 2032, Predicts DelveInsight | Key Companies to Watch Out - Cytokinetics, Orphazyme, Orion,...
Spinogenix Receives Approval from the Australia Human Research Ethics Committee to Initiate a Phase 1 Human Clinical Trial of SPG302, a Novel Regenerative Drug for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
July 10, 2023 05:00 ET
|
Spinogenix, Inc.
SAN DIEGO, July 10, 2023 (GLOBE NEWSWIRE) -- Spinogenix, Inc., a clinical-stage biopharmaceutical company developing novel small molecule drugs for neurological conditions, today announced that it...
Athira Pharma Announces Upcoming Presentations at the Alzheimer’s Association International Conference (AAIC) 2023
July 06, 2023 07:00 ET
|
Athira Pharma, Inc.
BOTHELL, Wash., July 06, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health...
PathMaker Neurosystems Receives $200,000 START Award from MassVentures
June 05, 2023 06:00 ET
|
PathMaker Neurosystems Inc.
BOSTON, June 05, 2023 (GLOBE NEWSWIRE) -- PathMaker Neurosystems Inc. (“PathMaker”), a near-commercial stage neuromodulation company developing breakthrough non-invasive systems for the treatment of...
AB Science annonce la délivrance d’un brevet canadien pour le masitinib dans le traitement de la SLA avec une protection jusqu’en 2037
June 01, 2023 12:01 ET
|
AB Science
PRESS RELEASE AB SCIENCE ANNONCE LA DÉLIVRANCE D'UN BREVET CANADIEN POUR LE MASITINIB DANS LE TRAITEMENT DE LA SCLÉROSE LATÉRALE AMYOTROPHIQUE (SLA) AVEC UNE PROTECTION JUSQU'EN 2037 CE BREVET...
AB Science announces issuance of a Canadian patent for masitinib in the treatment of ALS with protection until 2037
June 01, 2023 12:01 ET
|
AB Science
PRESS RELEASE AB SCIENCE ANNOUNCES ISSUANCE OF A CANADIAN PATENT FOR MASITINIB IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) WITH PROTECTION UNTIL 2037 CANADIAN PATENT COMPLETES...
Wave Life Sciences Announces Topline Results from Phase 1b/2a FOCUS-C9 Study of WVE-004 for C9orf72-associated Amyotrophic Lateral Sclerosis and Frontotemporal Dementia
May 23, 2023 07:30 ET
|
Wave Life Sciences USA, Inc.
Potent and durable target engagement observed across cohorts, including with 10 mg doses administered every 12 weeks which were also generally safe and well-tolerated WVE-004 did not show clinical...